India, Nov. 7 -- Baird Medical Investment Holdings Limited (BDMD), a medical device company, on Friday announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) and for a European Conformity (CE) certificate in the EU for an Irreversible electroporation system. The submission was carried out by its strategic partner, Tianjin Yuanshan Medical Technology Co. Ltd. (Alpmed).
Irreversible electroporation (IRE) is an advanced, minimally invasive, non-thermal ablation technology with potential uses in the resection of cancerous masses for a range of tumor types. IRE uses short pulses of high voltage to create permanent nanopores in cell membranes, causing apoptotic cell death in the targeted tissue...